pharma · Colorectal Neoplasms · Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang Rongyao Biotech
Zhejiang University
Zhejiang University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Colorectal Neoplasms, Borderline Resectable Pancreatic Adenocarcinoma. NovaPharmaNews links 2 clinical program(s),
CN HQ
1999 Founded
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 1999
- Employees
- 5
- Programs
- 2
- Drugs
- 3
- Patents
- 0
HRS-4642+AG+Nimotuzumab
Phase 2 · small molecule · Borderline Resectable Pancreatic Adenocarcinoma
HRS-4642+AG+Nimotuzumab for Borderline Resectable Pancreatic Adenocarcinoma is a Phase 2 program (small_molecule) at Zhejiang University with 1 ClinicalTrials.gov record(s).
Internal code CAPT05
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zhejiang University
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Borderline Resectable Pancreatic Adenocarcinoma
- Status
- active
- Trials
- 1